For example, in BALB/c mice, the tetravalent dengue ED3-based DNA vaccine induced one cross-reactive CD4+ T-cell epitope shared by DENV-1,?2, and?3 and one serotype-specific CD4+ T-cell epitope to DENV-4. to DENV-2 was boosted in rMV-TDV-immunized mice after challenge. This result suggested that pre-existing DENV-3-dominated T-cell reactions did not cross-react, but a DENV-2-specific IFN- response, which was undetectable during immunization, was recalled. Interestingly, this recalled T-cell response identified the epitope in the same position as the E349?363 Miglustat hydrochloride but in the DENV-2 serotype. This result suggested that immunodomination occurred in the CD4+ T-cell epitopes between dengue serotypes after rMV-TDV vaccination and resulted in a DENV-3-dominated CD4+ T-cell response. Even though significant increase in IgG against both DENV-2 and -3 suggested that cross-reactive antibody reactions were boosted, the improved neutralizing antibodies and IgG avidity still remained DENV-2 specific, consistent with the serotype-specific T cell response post challenge. Our data reveal that immunodomination caused a biased T-cell response to Ptgs1 one of the dengue serotypes after tetravalent dengue vaccination and focus on the tasks of cross-reactive T Miglustat hydrochloride Miglustat hydrochloride cells in dengue safety. Keywords: dengue, dengue vaccine, recombinant measles disease, immunodominance, envelope protein, AG129 mice Summary Evidence from cohort studies has shown styles of T-cell epitopes shifting to conserved areas following multiple rounds of illness, but the mechanism is unclear. Because of resource limitations, CD4+ T cells can identify only a small fraction of the epitopes within a complex virus, a trend called immunodominance. Immunodomination is the action of immunodominant T-cells suppressing the reactions to additional subdominant epitopes, which can be switched to dominating epitopes if a large amount of antigen without the immunodominant T-cell epitope is definitely offered. The subdominant epitopes perform an important part in preventing disease escape through mutations in the immunodominant T-cell epitope and have been reported to be involved in protecting immunity against influenza and additional viruses illness. Here, we 1st reported that immunodomination occurred between Miglustat hydrochloride serotype-specific CD4+ T-cell epitopes after immunization having a tetravalent MV-vectored dengue vaccine, and the DENV-3 epitope became an immunodominant epitope limiting the immune reactions to additional serotype epitopes; however, the subdominant DENV-2-specific CD4+ T-cell epitope switched to a dominating epitope after DENV-2 challenge. Consequently, serotype-specific T-cell epitopes suppress each other by immunodomination but not in conserved T-cell epitopes. Our results Miglustat hydrochloride provide a mechanism to explain why conserved dengue T-cell epitopes remain in T-cell epitope repertoires after multiple rounds of heterotypic dengue illness. Intro Dengue is the most common mosquito-borne viral disease in tropical and subtropical areas, and more than half of the global human population is at the risk of dengue illness (1). Approximately 390 million infections and 12,500 deaths yearly are caused by the four serotypes of dengue disease (DENV-1 to 4), primarily influencing Southeast Asia and Latin America (2C4). DENV infections are usually asymptomatic or cause self-limited febrile illness but occasionally develop into dengue fever and even life-threatening severe dengue, which is definitely characterized by plasma leakage, shock, severe bleeding, and severe organ involvement based on the WHO recommendations (5). The risk factors for severe dengue are still uncertain, but it has been proposed that antibody-dependent enhancement (ADE) and/or cross-reactive T cells are associated with the disease enhancement observed during a second heterotypic DENV illness (6C8). Although DENV-specific neutralizing antibodies provide safety from viral illness, paradoxically, as the antibody titers wane the pre-existing suboptimal antibodies facilitate DENV access into Fc receptor-bearing cells (9C11), such as dendritic cells,.